a total of three new shares were listed today, including Yike food on the gem, Maiwei biology on the science and innovation board, and Hujiang materials on the Beijing stock exchange.
Among them, Yike food is China’s leading large-scale poultry food enterprise and China’s top three meat and poultry supply enterprise . Its business runs through the whole industry value chain such as poultry (broiler and duck) variety breeding, breeding poultry breeding, feed, slaughtering, conditioning products and cooked food chain. The annual income of exceeds 15 billion yuan.
Maiwei biology is an innovative biopharmaceutical enterprise, whose main products are antibody drugs. it is worth noting that Maiwei biology is the 13th biomedical enterprise listed on the science and innovation board according to the fifth set of standards. According to the prospectus, Maiwei biology has not yet made a profit, has no products on the market and has no sales revenue. 9mw0113 is a recombinant human anti TNF developed by Maiwei biology in cooperation with Shanghai Junshi Biosciences Co.Ltd(688180) – α Monoclonal antibody injection is the closest product to the commercialization of Maiwei biology. It is expected to obtain the marketing license in the first quarter of 2022.
Hujiang materials, the second new share of the Beijing stock exchange, is a leading enterprise in the subdivision track of aluminum-plastic composite heavy packaging. The downstream customers of the company are mainly leading enterprises in the chemical industry, such as BASF, DSM and other multinational companies. The company occupies a place in the subdivision field of high barrier industrial flexible packaging.
in addition, four new shares were subscribed today, namely Juncheng technology and Tongguan copper foil of gem, Weide information and Zhenlei technology of Kechuang board.
Juncheng technology is mainly engaged in the R & D, design, production and sales of customized LCD products, the main products are various types of LCD screens and modules.
Tongguan copper foil is mainly engaged in the R & D, manufacturing and sales of various high-precision electronic copper foils. The main products are PCB copper foil and lithium battery copper foil. The P / E ratio of company is nearly 250 times, while the P / E ratio of the industry is less than 50 times. The company is a holding subsidiary of Tongling Nonferrous Metals Group Co.Ltd(000630) .
Weide information is a technological innovation enterprise in the field of information security of power distribution network. It is mainly engaged in the R & D, production and sales of intelligent security equipment and information security cloud platform, and provides customers with an overall solution for industrial Internet information security based on the above products.
Zhenlei technology is mainly engaged in the R & D, production and sales of integrated circuit chips and Microsystems, and provides technical services around related products. downstream customers are mainly subordinate enterprises and scientific research institutes of major military industry groups in China, with good business reputation and solvency.
For Maiwei biological products listed today, Shenwan Hongyuan Group Co.Ltd(000166) indicates that 9mw0113 independently developed by the company is a biological analogue of adalimumab. 9mw0311 is a similar drug of desuzumab prolide and 9mw0321 is a similar drug of desuzumab angavir.
For the industry development and competition pattern of Maiwei biology, Guotai Junan Securities Co.Ltd(601211) indicates that the biological drug market is developing rapidly. It is estimated that the market scale in China will reach 712.5 billion yuan in 2024. From the specific products of Maiwei biology, adalimumab’s market penetration in China is expected to increase rapidly , and the market scale is expected to reach 24.011 billion yuan in 2030. desumumab is the only anti RANKL monoclonal antibody drug approved for marketing in the world, which is expected to reach 10.661 billion yuan in 2030.
